晚期EGFR突变型非小细胞肺癌接受埃克替尼治疗疗效和循环肿瘤细胞的关系  

The relationship between the efficacy of ectopic treatment and circulating tumor cells in patients with advanced EGFR mutant non-small cell lung cancer

作　　者：黄韵坚[1] 黄诚[1] 庄武[1] 徐海鹏[1] 黄章洲[1] 徐振武[1] 吴标[1] 许春伟[2] 陈刚[2] Huang Yunjian;Huang Cheng;Zhuang WU;XU Haipeng;Huang Zhangzhou;Xu Zhenwu;Wu Biao;Xu Chunwei;Chen Gang(Medical oncology,Fujian Tumor Hospital Affiliated to Fujian Medical University,Fujian,Fuzhou,350014,China;Pathology department,Fujian Tumor Hospital Affiliated to Fujian Medical University,Fujian,Fuzhou,350014,China)

机构地区：[1]福建医科大学附属福建省肿瘤医院胸部肿瘤内科,福建福州350014 [2]福建医科大学附属福建省肿瘤医院病理科,福建福州350014

出　　处：《当代医学》2018年第25期105-109,共5页Contemporary Medicine

基　　金：国家临床重点专科建设项目(2013);福建省科技厅引导性项目(2015Y0011);福建省科技厅引导性项目(2016Y0019);吴阶平医学基金会课题(320.6750.14283)

摘　　要：目的评价晚期表皮生长因子受体(EGFR)突变型非小细胞肺癌中外周血循环肿瘤细胞(CTC)与埃克替尼疗效的关系。方法 74例晚期EGFR突变型非小细胞肺癌患者基于中位CTC数量被分为CTC低数量组和CTC高数量组,所有患者进行埃克替尼治疗,比较治疗疗效和预后。结果 CTC低数量组治疗有效率为46.88%(15/32),CTC高数量组治疗有效率为23.81%(10/42)。CTC低数量组中位OS为22.0个月(95%CI:19.6~28.7个月),CTC高数量组中位OS为18.3个月(95%CI:15.3~25.4个月)。结论 CTC低数量的晚期EGFR突变型非小细胞肺癌患者使用埃克替尼可以取得更好的疗效,CTC数量及治疗前后变化情况或可作为埃克替尼疗效的预测指标。Objective To evaluated the relationship between peripheral blood circulating tumor cells （CTC） and the efficacy of Exotinil in ad- vanced epidermal growth factor receptor （EGFR） mutant non-small cell lung cancer. Methods 74 patients with advanced EGFR mutant non-small cell lung cancer were divided into low- CTC group and high CTC group according to the median CTC count. All patients were treated with ectopic. The therapeutic efficacy and prognosis were compared. Results The effective rate of CTC lowdose group was 46.88% （15/32）, while the effective rate of CTC high volume group was 23.81% （10/42）. The median OS was 22.0 months （95% CI： 19.6-28.7 months） in the low- CTC group and 18.3 months （95% CI： 15.3-25.4 months） in the high CTC group. Conclusion Ectinib has a better therapeutic effect in patients with advanced EGFR mutant non-small cell lung cancer with lownumber of CTC. The number of CTC and changes before and after treatment may be used as predictors of the efficacy of ecitinib.

关 键 词：非小细胞肺癌 循环肿瘤细胞 埃克替尼 CanPatrolTM 

分 类 号：R734.2[医药卫生—肿瘤]